If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Evolution ponders Panmure bid

Thu, 23rd Sep 2010 17:03
Broker and fund manager Evolution Group says that it is considering a bid for AIM-quoted broker Panmure Gordon. Evolution says that a Panmure offer is one of a number of options under consideration. No formal discussions have taken place with Panmure. Evolution says it is waiting to assess Panmure's interim results which will be announced on 29 September. Panmure points out that revenues are skewed towards the second half so the interim figures may not be that informative. The Panmure board argues that its 46.8% shareholder QInvest is supportive of its strategy.

Related News

TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well
25 Apr 2024

TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests
4 Apr 2024

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat
19 Mar 2024

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reporte...

EVG.L News

IN BRIEF: Evgen Pharma files brain tumour treatment request with FDA
13 Jul 2021

IN BRIEF: Evgen Pharma files brain tumour treatment request with FDA

IN BRIEF: Evgen Pharma files brain tumour treatment request with FDA

IN BRIEF: Evgen Pharma encouraged by early data for SFX-01
13 Jul 2021

IN BRIEF: Evgen Pharma encouraged by early data for SFX-01

IN BRIEF: Evgen Pharma encouraged by early data for SFX-01

AIM WINNERS & LOSERS: Star Phoenix wins new deal; Ebiquity revenue up
13 Jul 2021

AIM WINNERS & LOSERS: Star Phoenix wins new deal; Ebiquity revenue up

AIM WINNERS & LOSERS: Star Phoenix wins new deal; Ebiquity revenue up

Evgen Pharma halts trial as SFX-01 drug fails to help Covid patients
9 Jul 2021

Evgen Pharma halts trial as SFX-01 drug fails to help Covid patients

Evgen Pharma halts trial as SFX-01 drug fails to help Covid patients

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle
9 Jul 2021

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

Evgen 'surprised and disappointed' by findings in SFX-01 trial
9 Jul 2021

Evgen 'surprised and disappointed' by findings in SFX-01 trial

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the results of the interim safety and futility assessment readout of...

UK shareholder meetings calendar - next 7 days
6 Jul 2021

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

TRADING UPDATES: GB Group rebuilds dividend; IPF ups 2021 profit view
15 Jun 2021

TRADING UPDATES: GB Group rebuilds dividend; IPF ups 2021 profit view

TRADING UPDATES: GB Group rebuilds dividend; IPF ups 2021 profit view